ReviewCurrent opinion in microbiology2019
Engineering enzymatic assembly lines to produce new antibiotics.
Review in Current opinion in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 79 citations in OpenAlex.
- Generative AI designs functional thiolation domains for reprogramming non-ribosomal peptide synthetases.Nature communications · 2026Article
- A Simple and Versatile Cell-Free Expression Method for Producing Secondary Metabolites.ACS synthetic biology · 2026Article
- Identification of the lydiamycin biosynthetic gene cluster in a plant pathogen guides structural revision and identification of molecular target.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Biosynthetic Pathways of Alaremycin and Its Derivative: Inhibitors of Porphobilinogen Synthase in Porphyrin Biosynthesis fromACS bio & med chem Au · 2025Article
- Engineering the future of medicine: Natural products, synthetic biology and artificial intelligence for next-generation therapeutics.Clinical and translational medicine · 2025Review
- Advances, opportunities, and challenges in methods for interrogating the structure activity relationships of natural products.Natural product reports · 2024Review
- Multiple pathways impact the swarming motility ofMicrobiology spectrum · 2024Article
- Multiple Pathways Impact Swarming Motility ofbioRxiv : the preprint server for biology · 2024Article
- Late-stage diversification of bacterial natural products through biocatalysis.Frontiers in bioengineering and biotechnology · 2024Review
- High-Throughput Engineering of Nonribosomal Extension Modules.ACS chemical biology · 2023Article
- Structural advances toward understanding the catalytic activity and conformational dynamics of modular nonribosomal peptide synthetases.Natural product reports · 2023Review
- Biosynthetic incorporation of fluorinated amino acids into the nonribosomal peptide gramicidin S.RSC chemical biology · 2023Article
- Guidelines for Optimizing Type S Nonribosomal Peptide Synthetases.ACS synthetic biology · 2023Article
- Advances in the adenylation domain: discovery of diverse non-ribosomal peptides.Applied microbiology and biotechnology · 2023Review
- Engineering Siderophore Biosynthesis and Regulation Pathways to Increase Diversity and Availability.Biomolecules · 2023Review
- Investigating and Optimizing the Lysate-Based Expression of Nonribosomal Peptide Synthetases Using a Reporter System.ACS synthetic biology · 2023Article
- Emulating nonribosomal peptides with ribosomal biosynthetic strategies.RSC chemical biology · 2023Review
- Genomic characterization ofFrontiers in microbiology · 2023Article
- Metabolic pathway assembly using docking domains from type I cis-AT polyketide synthases.Nature communications · 2022Article
- NMR as a readout to monitor and restore the integrity of complex chemoenzymatic reactions.Journal of magnetic resonance (San Diego, Calif. : 1997) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Numerous important therapeutic agents, including widely-used antibiotics, anti-cancer drugs, immunosuppressants, agrochemicals and other valuable compounds, are produced by microorganisms. Many of these are biosynthesised by modular enzymatic assembly line polyketide synthases, non-ribosomal peptide synthetases, and hybrids thereof. To alter the backbone structure of these valuable but difficult to modify compounds, the respective enzymatic machineries can be engineered to create even more valuable molecules with improved properties and/or to bypass resistance mechanisms. In the past, many attempts to achieve assembly line pathway engineering failed or led to enzymes with compromised activity. Recently our understanding of assembly line structural biology, including an appreciation of the conformational changes that occur during the catalytic cycle, have improved hugely. This has proven to be a driving force for new approaches and several recent examples have demonstrated the production of new-to-nature molecules, including anti-infectives. We discuss the developments of the last few years and highlight selected, illuminating examples of assembly line engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.